Body Pharm CJC1295 & Ipamorelin 20 Pen

Body Pharm CJC-1295 & Ipamorelin 20 Pen: Full SA Guide

The Body Pharm CJC-1295 & Ipamorelin 20 Pen is a pre-loaded multi-dose injector pen sold in South Africa containing a blended CJC-1295 (without DAC) and ipamorelin peptide solution, dialled in micrograms and injected subcutaneously. It retails at R2,000 for a 20 mg pen as of January 2026, and because it is self-administered it avoids the labour cost that comes with clinic-delivered injection cycles.

Key Takeaways

• The pen delivers 10 mg CJC-1295 + 10 mg ipamorelin in a prefilled dial-a-dose format; dialling 200 mcg gives 200 mcg of each peptide, not 200 mcg combined.
• Standard dosing is 100–200 mcg once daily before sleep on an empty stomach; cycles run 8–12 weeks on, 4 weeks off. This is practitioner-consensus guidance, not an approved protocol.
• The pen costs R2,000 per cycle and removes reconstitution steps, making it faster and more accurate than vials but more expensive per milligram in bulk.
• Neither peptide is named in SAHPRA’s published schedules as of 2026, placing them in a regulatory grey zone; consult a registered GP before starting.
• Each batch is independently HPLC-tested: the published certificate of analysis for this pen reports 99.09% purity.
• Expected benefits include deeper sleep within 1–2 weeks, improved recovery by week 3–4, and visible body composition changes from week 6–8 onward; no 2020–2026 RCT confirms these timelines for the combination.
• Side effects are typically mild and localised (injection-site redness, transient water retention, tingling); serious contraindications include active cancer, pregnancy, uncontrolled diabetes, and age under 18.

This guide answers five core questions:

1. How to dial, time, and inject each dose correctly.
2. How to store the pen and what its real shelf life looks like.
3. How an 8–12 week cycle is typically structured.
4. How the pen compares to vials and clinic-compounded options on price, accuracy, and sterility.
5. Where CJC-1295 and ipamorelin sit under SAHPRA rules in 2026.

Neither peptide appears by name in SAHPRA’s published schedules as of 2026, yet both were placed by the U.S. FDA on its Category 2 list of bulk substances flagged as potentially presenting significant safety risks for pharmacy compounding. That gap is why dosing precision and honest sourcing matter more than marketing claims.

What this guide adds

Three practical pieces of information that most South African buyers struggle to find are covered below: a dial-specific dose translation (the Body Pharm pen reads micrograms per peptide, not combined), a like-for-like comparison of the pen against clinic-administered and compounded-vial routes on price and accuracy, and a plain-language read on SAHPRA’s 2026 position. All three are below.

What Is the Body Pharm CJC-1295 & Ipamorelin 20 Pen?

The Body Pharm CJC-1295 & Ipamorelin 20 Pen is a prefilled multi-dose injector pen containing 10 mg of CJC-1295 (without DAC) plus 10 mg of ipamorelin, totalling 20 mg of peptide per pen, retailing at R2,000 as of January 2026. Body Pharm manufactures it and sells it through South African online peptide retailers.

Facts the buyer needs upfront:

1. Format: prefilled subcutaneous injector pen, dosed in micrograms via a dial mechanism, not a glass vial requiring separate reconstitution or syringe draw-up.
2. Active ingredients: CJC-1295 (no DAC) 10 mg + ipamorelin 10 mg, premixed in a single cartridge.
3. Drug class: growth hormone secretagogue stack. The pen prompts the pituitary gland to release endogenous GH. It does not contain somatropin or any exogenous human growth hormone.
4. Price: R2,000 per 20 mg pen as of January 2026. Because it is self-administered, it avoids the added labour cost that clinic-delivered injection cycles carry.
5. Batch testing: Body Pharm publishes a batch-specific certificate of analysis for this pen. The certificate for batch CJIP9837 reports 99.09% purity by HPLC and 5.2 mg/mL of each peptide (10.4 mg of CJC-1295 and 10.4 mg of ipamorelin per 3 mL cartridge). It does not, however, publish a separate validated in-use stability data sheet.

A prefilled peptide pen differs from a vial in one practical sense: the peptide is already reconstituted in solution and the dose is dialled in micrograms on the barrel, so no bacteriostatic water, mixing, or insulin-syringe measurement is needed. Readers comparing pens across the Body Pharm range can look at the Body Pharm Tesamorelin 32 Pen (a GHRH analogue) or the Body Pharm MOTS-C 32 Pen (a mitochondrial-derived metabolic peptide).

How CJC-1295 and Ipamorelin Work Together

CJC-1295 and ipamorelin stimulate two different receptors on the pituitary simultaneously. That dual-receptor activation is intended to produce a larger GH pulse than either peptide alone.

CJC-1295 is a synthetic Growth Hormone Releasing Hormone (GHRH) (1-29) analogue that binds the GHRH receptor; in healthy adults a single subcutaneous dose has been shown to raise circulating GH and IGF-1 for several days. Ipamorelin is a selective growth-hormone secretagogue and ghrelin-mimetic that binds the GHSR-1a ghrelin receptor. Combined, they are proposed to raise both the frequency and amplitude of natural GH release.

Once injected, the sequence runs like this:

1. CJC-1295 docks at the GHRH receptor on pituitary somatotrophs and signals them to prepare a GH pulse.
2. Ipamorelin docks at the ghrelin receptor (GHSR-1a) on the same cells and amplifies the size of that pulse.
3. The pituitary releases stored endogenous GH in a pulse pattern that mimics natural physiology, rather than producing a flat, supraphysiological level.
4. The liver responds to the GH pulse by producing IGF-1 (Insulin-like Growth Factor 1), the downstream mediator most fat-loss and recovery claims hinge on.
5. GH returns to baseline within hours, preserving the normal pulsatile rhythm and negative-feedback loop.

Ipamorelin is reported to have minimal effect on cortisol and prolactin compared with older GHRPs like GHRP-2 and GHRP-6, because its receptor selectivity is narrower than earlier-generation compounds. This rests on pre-2020 human and preclinical data and has not been re-tested in recent randomised trials.

How this differs from exogenous HGH

This stack is not human growth hormone. The Body Pharm Somatropin 40 Pen delivers recombinant HGH directly into the bloodstream, bypassing the pituitary entirely, because it is exogenous hormone rather than a secretagogue. The CJC-1295/ipamorelin pen prompts your own pituitary to release its own GH, which is why the effect is pulsatile rather than continuous. For other GHRH-class options in the same pen format, see the Body Pharm Tesamorelin 32 Pen, or for a non-GH metabolic peptide, the Body Pharm MOTS-C 32 Pen.

Pen vs Vial: Which Format Should You Choose?

The pen wins on convenience and dose accuracy because the dial mechanism removes user-measurement error. The vial wins on cost per milligram if you buy in bulk and tolerate the extra steps. Below is the side-by-side most South African buyers ask for but rarely find.

Dimension	Body Pharm CJC-1295/Ipamorelin 20 Pen	Traditional vial + insulin syringe
Dose accuracy	Dial-graduated, mechanical click stops	Visual draw against syringe markings; ±10–20% user error common
Steps per injection	3 (cap off, dial, inject)	7+ (reconstitute, swab, draw, expel air, verify, inject, discard)
Reconstitution	None. Prefilled, ready to use	Required. Bacteriostatic water sourced separately
Cold chain	2–8 °C, return to fridge after use	2–8 °C pre- and post-reconstitution
Cost per dose	Higher per mcg, lower per cycle in time/waste	Typically cheaper per mg in bulk (e.g. a 1,000 mcg/mL multi-dose vial), but needs manual measurement
Portability	Travel-friendly, no loose syringes	Requires vial, syringes, swabs, sharps container

When the pen is the better buy

Pick the pen if this is your first peptide cycle, if you travel, or if you have ever miscounted units on an insulin syringe at 5am. The dial removes the most common failure point in self-administered peptide therapy: drawing the wrong volume from a reconstituted vial.

When the vial still makes sense

Pick the vial if you are running long, repeated cycles and have a steady supplier through a compounding pharmacy, because bulk vial pricing is lower per milligram over multiple cycles. Compounding pharmacies typically stock a 1,000 mcg/mL multi-dose vial format that experienced users prefer for cost control. A fully outsourced, nurse-delivered clinic protocol is the most convenient route but the most expensive of the three, because it includes clinical labour.

If you are weighing other pen-format peptides in the same product family, the Body Pharm Tesamorelin 32 Pen and Body Pharm MOTS-C 32 Pen use the same dial-and-inject mechanism, so the format logic above carries across.

Step-by-Step: How to Use the Body Pharm Pen

Remove the pen from the fridge, dial your dose, inject subcutaneously into the abdomen, and return it to the fridge. These steps apply only to the Body Pharm CJC-1295 & Ipamorelin 20 Pen, not to vial-and-syringe products.

1. Remove the pen from the refrigerator 5–10 minutes before injecting. Cold peptide solution stings going in. Let it reach room temperature on a clean surface.
2. Wipe the injection site with an alcohol swab. The lower abdomen, two finger-widths from the navel, is the standard subcutaneous injection site because this area has consistent subcutaneous depth and minimal nerve density.
3. Attach a fresh pen needle and prime if the pen is new. Discard a 1–2 mcg test drop on first use to clear air from the cartridge.
4. Dial your dose. On the Body Pharm pen, dialling 200 mcg delivers 200 mcg CJC-1295 plus 200 mcg ipamorelin in the same shot (per the Body Pharm product spec, January 2026). Dialling 300 mcg delivers 300 mcg of each peptide, not 300 mcg total. Read this twice before your first injection.
5. Pinch a fold of subcutaneous tissue at the swabbed site. This lifts the fat layer away from muscle, ensuring the needle deposits into subcutaneous tissue rather than intramuscular space.
6. Insert the needle at 45–90 degrees and press the plunger slowly. Hold for 5–10 seconds after the dial returns to zero so the full dose deposits.
7. Withdraw the needle and apply light pressure with a clean tissue. No massage. A small bead of blood is normal.
8. Remove and bin the needle in a sharps container, then return the pen to the fridge immediately.

Dose-dial cheat sheet

• Dial 100 mcg = 100 mcg CJC-1295 + 100 mcg ipamorelin
• Dial 200 mcg = 200 mcg of each
• Dial 300 mcg = 300 mcg of each

The dial reads per peptide, not combined. If you have previously used a vial protocol calling for “200 mcg combined,” you would dial 100 mcg on this pen because the pen’s dial delivers both peptides simultaneously. Users cross-shopping the Body Pharm Tesamorelin 32 Pen or Body Pharm MOTS-C 32 Pen will recognise the same dial mechanism, but the per-click microgram values differ between products.

CJC-1295 & Ipamorelin Dosing Guide (2026)

A typical Body Pharm pen dose is 100–200 mcg of each peptide per injection for beginners, rising to 200–300 mcg of each for maintenance, administered subcutaneously once daily, 30–60 minutes before sleep on a 2–3 hour empty stomach. This timing stacks the peptide pulse onto the body’s natural nocturnal GH wave. Cycles usually run 8–12 weeks on, 4 weeks off. This guidance is practitioner consensus, not a SAHPRA-registered protocol.

Recommended dosing protocol

1. Week 1–2 (assessment): Dial 100 mcg. This delivers 100 mcg CJC-1295 + 100 mcg ipamorelin. Watch for flushing, head-rush, or unusual hunger.
2. Week 3 onward (standard): Dial 200 mcg once daily. Most adult users settle here.
3. Advanced (week 4+): Dial up to 300 mcg if tolerated and clinically appropriate. Going above 300 mcg per shot offers diminishing GH-pulse returns and raises side-effect risk.
4. Cycle: Run 8–12 weeks, then take 4 weeks off to let receptor sensitivity reset. A 4-week minimum off-cycle is the interval most commonly used to let receptor sensitivity recover.

Injection timing

Inject 30–60 minutes before bed on a relatively empty stomach (2–3 hours after your last meal). Food, especially carbs and fats, blunts GH release by raising insulin and free fatty acids, which suppress GHRH signalling. Post-workout is a viable secondary slot if bedtime dosing does not suit your schedule. Keep at least two hours between food and injection either way.

Important dosing caveats

• The dial values above apply only to the Body Pharm CJC-1295 & Ipamorelin 20 Pen. Do not transfer this scheme to vials, compounded syringes, or other pen products. The Body Pharm Tesamorelin 32 Pen and Body Pharm MOTS-C 32 Pen use different per-click microgram values.
• No 2020–2026 randomised trial confirms specific body-composition outcomes from CJC-1295 + ipamorelin combined. Dose claims rest on mechanistic reasoning and clinic experience.
• Consult a registered GP or endocrinologist before starting, particularly if you have diabetes, active cancer, or take thyroid or corticosteroid medication.
• Body recomposition responses vary with training status, protein intake, and sleep quality.

Expected Benefits: Fat Loss, Muscle, Sleep & Recovery

Users typically report benefits in this order: better sleep quality within 1–2 weeks, improved recovery and tissue repair by week 3–4 as IGF-1 rises, and visible body composition changes from week 6–8 onward. No 2020–2026 randomised trial confirms these timelines for the CJC-1295 + ipamorelin combination specifically. Treat the list below as mechanistically plausible, not clinically proven.

What the peptide pen may support

Deeper sleep. GH releases predominantly during slow-wave sleep. Injecting 30–60 minutes before bed is intended to stack with that natural pulse, amplifying the depth of slow-wave phases. Sleep improvement is the most consistently reported subjective benefit in clinic write-ups, though not confirmed by RCT for this combination.

Recovery and soft-tissue repair. Higher IGF-1 from GH stimulation supports collagen synthesis and post-training repair because IGF-1 is a primary driver of fibroblast activity. Expect this to show as faster gym recovery and less next-day stiffness rather than dramatic strength gains.

Lean muscle development. GH-driven IGF-1 elevation supports protein synthesis through mTOR pathway activation. The peptide is not anabolic in the way testosterone or trenbolone are. Without training and adequate protein, do not expect muscle gain.

Fat loss, especially visceral. GH promotes lipolysis and preferentially mobilises visceral adipose tissue because visceral fat is more metabolically active and GH-sensitive than subcutaneous depots. Subcutaneous fat loss is slower and less predictable. If fat loss is your primary goal, the weight loss injections category has GLP-1 alternatives with stronger clinical data.

Skin and “anti-ageing” effects. This is the weakest evidence base. Claims of skin thickness, wrinkle reduction, or general rejuvenation rest on mechanistic reasoning, not trials.

The common rationale, that GH output falls roughly 14% per decade of adult life, comes from older longitudinal endocrinology data, not a recent 2020s cohort study. Worth knowing if you are weighing this pen against the Body Pharm Tesamorelin 32 Pen (more visceral-fat focused) or the Body Pharm MOTS-C 32 Pen (metabolic, mitochondrial angle).

CJC-1295 & Ipamorelin Side Effects: What to Know

The most commonly reported side effects of CJC-1295 and ipamorelin are mild and localised: injection site redness, transient water retention, early-cycle lethargy, and tingling or numbness in the hands. Elevated GH can cause fluid shifts and temporary nerve compression. These tend to settle within the first 1–2 weeks as the body adjusts to elevated GH pulses.

Less frequently reported effects include headache, facial flushing shortly after injection (from vasodilation), vivid dreams (from increased slow-wave sleep), and mild appetite increase from the ghrelin-receptor activity of ipamorelin. If symptoms persist past two weeks or worsen, drop the dose or stop and consult a doctor.

In its original characterisation study, ipamorelin did not raise cortisol or prolactin above levels seen with GHRH alone, unlike older GHRPs such as GHRP-6 and GHRP-2, because its receptor selectivity avoids the prolactin-stimulating pathways those compounds activate. That finding rests on earlier human and preclinical trials, not a recent randomised confirmatory study. Treat it as a reasonable expectation, not a guarantee.

Long-term safety data for the CJC-1295 + ipamorelin combination in healthy adults is limited as of 2026, with no peer-reviewed RCTs on chronic use.

Do not use this pen if any of the following apply:

1. Active or recently treated cancer (growth-hormone products are contraindicated in active malignancy because GH and IGF-1 elevation may stimulate tumour growth).
2. Pregnancy or breastfeeding.
3. Uncontrolled type 2 diabetes or significant insulin resistance (GH is counter-regulatory to insulin).
4. Active pituitary disease or untreated hypothyroidism.
5. Concurrent use of somatropin or other GH-axis medications without medical supervision.
6. Under 18, or without a medical assessment if over 65.

This list is not exhaustive. Book a consult with a GP or endocrinologist before starting, especially if you take chronic medication. Users comparing safety profiles across the peptide-pen range can look at the Body Pharm Tesamorelin 32 Pen or the metabolic-focused Body Pharm MOTS-C 32 Pen for context.

Storage & Shelf Life: Keeping Your Pen Effective

Store the Body Pharm CJC-1295 & Ipamorelin 20 Pen refrigerated at 2–8°C, protected from light, and never frozen. Freezing fractures peptide bonds and denatures the active compounds. Body Pharm’s product listing specifies refrigerated, light-protected storage, with no freezing.

Every batch is released against an HPLC certificate of analysis — the certificate for batch CJIP9837 reports 99.09% purity — so a genuine, correctly stored cartridge should run clear. In-use stability for reconstituted GHRH/GHRP peptide pens is commonly cited as 28–30 days refrigerated because this window reflects typical bacterial-growth lag in sealed cartridges. Body Pharm has not published a separate validated in-use stability data sheet for this specific pen, so treat 28 days as a conservative working window and discard sooner if the solution turns cloudy or discoloured.

Practical handling rules:

1. Return the pen to the fridge within 30 minutes of injecting. Do not leave it on the bathroom counter all day.
2. For travel, pack the pen in a small insulated cooler bag with a frozen gel pack wrapped in cloth, so the pen stays cold but never touches ice directly.
3. Do not use past the printed expiry, even if clicks remain.
4. If the pen is accidentally left at room temperature for more than 4–6 hours, consider it compromised.
5. Inspect the cartridge before every shot. Clear solution is fine; cloudy or particulate solution is not.

Improper storage is the most common reason users report “the pen stopped working.” It is almost never the peptide. It is the fridge door, the summer car ride, or the freezer shelf.

SAHPRA Status & Buying Legally in South Africa (2026)

CJC-1295 and ipamorelin are not registered therapeutic medicines with the South African Health Products Regulatory Authority (SAHPRA) as of January 2026, and neither peptide appears by name in the current Schedules to the Medicines and Related Substances Act. They are not classified alongside anabolic steroids, but they are not approved medicines either. This puts them in a regulatory grey zone.

For context, the U.S. FDA has placed both peptides on its Category 2 list of bulk substances that may present significant safety risks for 503A pharmacy compounding, citing concerns that include potential carcinogenicity, immunogenicity, and impurities. South African practice has evolved separately. Local clinics and compounding pharmacies generally dispense CJC-1295/ipamorelin under prescription, treating them as if Schedule 4, based on professional interpretation rather than a named SAHPRA entry.

Competitive and drug-tested athletes should also note that both CJC-1295 (a GHRH analogue) and ipamorelin (a growth-hormone secretagogue) are prohibited at all times, in and out of competition, under the WADA Prohibited List.

Three buying routes, briefly

1. Personal-use online purchase (e.g. direct retail of the Body Pharm pen via beskinny.store). Lowest oversight, highest personal responsibility. A batch certificate of analysis is published for this pen, which helps confirm authenticity but does not substitute for medical supervision.
2. Practitioner-supervised use via a registered doctor who scripts and monitors bloods. The most defensible route.
3. Compounding-pharmacy supply under prescription, and nurse-delivered administration services, which sit closer to the supervised end of the spectrum.

Consult a registered healthcare practitioner before starting. Verify SAHPRA’s current position at the time you buy. This page is information, not legal or medical advice. Users weighing peptide options may also be reviewing the Body Pharm Tesamorelin 32 Pen or Body Pharm MOTS-C 32 Pen, which sit in the same unregistered category.

How the Body Pharm Pen Compares to Similar Products

The Body Pharm pen wins on price and convenience because it eliminates reconstitution steps and clinical labour. Clinic and compounded routes win on supervision and dose flexibility. Here is the side-by-side as of January 2026.

Option	Price (January 2026)	Format	Supervision	Where
Body Pharm CJC-1295 & Ipamorelin 20 Pen	R2,000	Pre-mixed pen, 20 mg total, dial-a-dose	Self-administered	beskinny.store
Clinic-administered cycle	Varies (typically higher)	Nurse-delivered injections, ~4 weeks	Full clinical supervision	Select clinics
Compounding-pharmacy vial	Script-dependent	1,000 mcg/mL vial, requires reconstitution + insulin syringe	Pharmacist-dispensed, prescription	Compounding pharmacies

Which route fits which buyer

Pick the pen if you have injected before, want a fixed cost, and prefer not to reconstitute powder, because the dial mechanism is faster and more accurate. Pick a clinic-administered cycle if you want a nurse to handle the needle. Pick a compounded vial if your prescriber wants a custom dose outside the pen’s 100 mcg dial increments.

If your goal is not GH-axis support

Two other Body Pharm pens sit on the same shelf for different goals. The Body Pharm Tesamorelin 32 Pen is a stronger GHRH analogue often chosen for visceral fat because it has more published clinical data on visceral-fat reduction. The Body Pharm MOTS-C 32 Pen targets mitochondrial and metabolic pathways rather than GH release.

Who Should (and Shouldn’t) Use This Pen

This pen suits healthy adults 30+ who want GH-axis support and have injected before, because this demographic typically has measurable GH decline and injection experience. It does not suit anyone with active cancer, pregnancy, breastfeeding, uncontrolled diabetes, or age under 18.

Good candidates

1. Adults 30+ noticing slower recovery, thinner sleep, and softer body composition, because GH secretion is commonly cited as declining roughly 14% per decade after young adulthood. This figure rests on older longitudinal data, not new 2020s cohorts.
2. Recreational and masters-level athletes prioritising recovery and lean muscle development over raw strength, because GH-axis support may help preserve muscle during training stress without the side effects of exogenous hormones.
3. People who want a non-anabolic alternative to testosterone or other AAS, working with the pituitary rather than overriding it.
4. Self-injectors who prefer a dial-a-dose pen to reconstituting powder and drawing with insulin syringes, because the dial removes the most common dosing error.

Who should skip it (or get clearance first)

1. Anyone with active or recent malignancy. GH and IGF-1 elevation in this group is a known concern.
2. Pregnant or breastfeeding women.
3. People with uncontrolled type 2 diabetes or significant insulin resistance, since GH is counter-regulatory to insulin.
4. Anyone under 18, or anyone on medication for a pituitary, thyroid, or adrenal condition without prescriber sign-off.

If fat loss is your primary goal, this is the wrong tool

CJC-1295/ipamorelin is not a weight-loss drug. No 2020–2026 RCT confirms meaningful fat loss from the combination in healthy adults. If the scale is the target, look at semaglutide or tirzepatide instead, because they work on appetite and glucose suppression, not the GH axis.

Frequently Asked Questions

The Body Pharm CJC-1295 & Ipamorelin 20 Pen contains 10 mg of each peptide, which yields approximately 50 injections at a 200 mcg dose. Answers below assume standard protocol use; verify specifics with a SA-registered prescriber before starting.

How many doses are in the pen?

At 200 mcg per injection, the pen delivers roughly 50 doses per peptide before it runs dry, because 10 mg ÷ 0.2 mg = 50. At 300 mcg you get around 33 doses. At 100 mcg, around 100. The math is straightforward: 10 mg ÷ your dose in mcg = injection count.

Can I buy and use the pen without a prescription in South Africa?

Neither CJC-1295 nor ipamorelin appears by name in SAHPRA’s published schedules as of January 2026, so they are not explicitly scheduled substances. In practice, SA clinics and compounding pharmacies dispense them under prescription as if they were Schedule 4 peptide therapies, because professional consensus treats them as controlled peptides. Get a consultation. It protects you medically and legally.

How long before I see results?

Most users report deeper sleep within 2 to 4 weeks of consistent nightly dosing, with visible body composition changes typically taking 8 to 12 weeks, because GH-driven changes in fat distribution and muscle protein synthesis require sustained elevation over multiple weeks. This timeline reflects practitioner consensus and uncontrolled clinic reports, not 2020–2026 randomised trial data.

Can I stack the pen with semaglutide or tirzepatide?

Some SA practitioners run CJC-1295/ipamorelin alongside GLP-1 or GIP/GLP-1 agonists to preserve lean mass during aggressive caloric deficits, because GH elevation may counteract the muscle-sparing challenge of rapid weight loss. There is no RCT confirming the safety or efficacy of this stack as of January 2026. If you are going this route, do it under supervision and review the tirzepatide product range separately first.

What happens if I miss a dose?

Skip it and resume your next scheduled injection. Do not double-dose to catch up. The GH pulse you missed is gone; doubling will not recreate it and may blunt receptor sensitivity.

Are there other peptide pens worth comparing?

Yes. The Body Pharm Tesamorelin 32 Pen is another GHRH analogue with stronger published data for visceral fat reduction. The Body Pharm MOTS-C 32 Pen targets mitochondrial metabolism rather than the GH axis, so it answers a different question entirely.

Next Steps

If the pen is the right fit, consult a registered GP or endocrinologist to confirm you have no contraindications, then order the Body Pharm CJC-1295 & Ipamorelin 20 Pen directly. If you fall into any of the caution categories above, book a prescriber consult first. If you are still cross-shopping, open the Tesamorelin 32 Pen and MOTS-C 32 Pen pages side by side and compare the dial mechanics, price per cycle, and target outcomes against this one.

References

1. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 2006.
2. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998.
3. Growth hormone in the aging male. Best Practice & Research Clinical Endocrinology & Metabolism, 2013.
4. Norditropin (somatropin) prescribing information. DailyMed, U.S. National Library of Medicine.
5. Certain bulk drug substances for use in compounding that may present significant safety risks. U.S. Food and Drug Administration, 2023.
6. Guideline to the scheduling of substances and medicines. South African Health Products Regulatory Authority (SAHPRA).
7. The Prohibited List. World Anti-Doping Agency, 2026.
8. Body Pharm CJC-1295 & Ipamorelin 20 Pen — certificate of analysis (batch CJIP9837). Body Pharm, 2026.